Evidence map›Paper›PMID 42713316›Full record

ArticleCureus2026

Under the Surface: A Rare Case of the En Coup De Sabre Subtype of Linear Morphea in the Rio Grande Valley.

Miguel Lopez, Jared Hensley, Maria Villegas

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Miguel LopezDermatology, University of Texas Rio Grande Valley School of Medicine, Edinburg, USA.
Jared HensleyDermatology, University of Texas Rio Grande Valley School of Medicine, Edinburg, USA.
Maria VillegasDermatology, University of Texas Rio Grande Valley School of Medicine, Edinburg, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Localized scleroderma, also referred to as 'morphea,' is a rare autoimmune disorder that affects the superficial layers of the skin and is characterized by both erythematous and bruise-like lesions with signs of central skin tightening or sclerosis; deeper lesions may be identified as edematous, erythematous plaques in the absence of well-defined borders. A subtype named en coup de sabre (ECDS) exists in the classification of linear morphea and presents with a linear induration on either the face or scalp. Our patient is a 21-year-old Hispanic female initially residing outside of the South Texas region who experienced an onset of skin thickening and blisters on her right leg in April of 2023 after returning from Europe. Initially, she was diagnosed as having stasis dermatitis, but due to progression of her cutaneous symptoms, a skin biopsy was performed in September of 2023, which confirmed a diagnosis of morphea. After 10 months of initial treatment with a dermatologist outside of South Texas, she presented to the UT Health Rio Grande Valley (UTRGV) dermatology specialty clinic (Edinburg, TX, USA) with new and evolving skin plaques across her body, along with a forehead lesion that was consistent with the ECDS subtype of linear morphea. During this time, care was also formally established with local rheumatology and wound care specialists who had a pivotal role in the management of her condition. This case discusses the variability in clinical presentation of morphea, its mixed nature of lesions, its progression, its varied response to medical therapy, and the need for multidisciplinary management.

Indexed as

cellcept (mycophenolate mofetil)en coup de sabre morpheahydroxychloroquine treatmentmorphea variantsplaque formationskin ulcers

Identifiers

PMID42713316
PMCPMC13552635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.